



9. An intermediate compound of general formula (1-5) according to claim 7,



whereby R^1 , R^6 , R^7 , R^8 and m have the meaning according to claim 1.

10. Use of a compound of formula 1-6 for the manufacture of a compound of formula (I) according to claim 1.

11. A compound of formula (1-4):



whereby R^1 , R^2 , R^3 , R^4 , R^6 and n have the meaning according to claim 1.

4412. A compound of general formula (I) according to any of claims 1 to 6 for use in the treatment or prophylaxis of diseases.

4213. The compound of general formula (I) according to claim 4412, whereby the diseases are hyperproliferative diseases and/or disorders responsive to induction of apoptosis.

4314. The compound of general formula (I) according to claim 4213, whereby the hyperproliferative diseases and/or disorders responsive to induction of apoptosis are haematological tumours, solid tumours and/or metastases thereof.

1415. The compound of general formula (I) according to claim 1414, whereby the tumors are cervical -, breast -, non-small cell lung -, prostate -, colon – or melanoma tumors and/or metastases thereof.

1516. A pharmaceutical composition comprising at least one compound of general formula (I) according to any of claims 1 to 6, together with at least one pharmaceutically acceptable auxiliary.

1617. A composition according to claim 15–16 for use in the treatment of haematological tumours, solid tumours and/or metastases thereof.

1718. A combination comprising one or more first active ingredients selected from a compound of general formula (I) according to any of claims 1 to 6, and one or more second active ingredients selected from chemotherapeutic anti-cancer agents and target-specific anti-cancer agents.

1819. Use of a compound of general formula (I) according to any of claims 1 to 6 in the manufacture of a medicament for the treatment or prophylaxis of diseases.

1920. The use according to claim 1819, whereby the diseases are hyperproliferative diseases and/or disorders responsive to induction of apoptosis.

2021. The use according to claim 1920, whereby the hyperproliferative diseases and/or disorders responsive to induction of apoptosis are haematological tumours, solid tumours and/or metastases thereof.

2122. The use according to claim 2021, whereby the tumors are cervical -, breast -, non-small cell lung -, prostate -, colon – or melanoma tumors and/or metastases thereof.

2223. Use of a composition according to claim 15–16 in the manufacture of a medicament for the treatment of haematological tumours, solid tumours and/or metastases thereof.